Welcome to our dedicated page for CLOVER HEALTH INVESTMENTS /DE SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CLOVER HEALTH INVESTMENTS /DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CLOVER HEALTH INVESTMENTS /DE's regulatory disclosures and financial reporting.
CLOV records a Form 144 notice covering the planned sale of 60765 shares of Class A Common Stock, to be sold through Morgan Stanley Smith Barney LLC on Nasdaq, dated 07/15/2026.
The shares arise from Restricted Stock Units granted by the issuer as compensation, with acquisition and payment dated 07/15/2026. The filing also lists 10b5-1 sales for Andrew Toy of 313476 shares of Class A Common Stock on 07/01/2026 for aggregate proceeds of 1667692.32 during the past three months.
CLOV discloses a planned sale of 23,463 shares of Class A Common Stock through Morgan Stanley Smith Barney LLC on July 15, 2026 on Nasdaq, with an aggregate market value of $109,806.84.
The shares derive from restricted stock units granted by the issuer as compensation and acquired on July 15, 2026. Over the prior three months, 220,426 shares of Class A Common Stock were sold for $879,499.74 under 10b5-1 Plan Sales for Conrad Wai.
Clover Health Investments, Corp. executive Jamie L. Reynoso, CEO of Medicare Advantage, reported an open-market sale of 2,384 shares of Class A Common Stock at $4.68 per share. After this transaction, Reynoso directly holds 2,832,598 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026, indicating it was scheduled in advance as part of a trading program rather than a discretionary one-time decision.
CLOV holder filed a Form 144 proposing the sale of 2,384 Restricted Stock Units. The notice lists the securities to be sold as Common — Restricted Stock Units totaling 2,384 with an effective date of 07/03/2026. The filing also lists prior 10b5-1 sales by Jamie Reynoso on 06/11/2026, 06/15/2026, 06/17/2026, and 07/06/2026 with individual share and proceeds amounts shown in the table.
Clover Health Investments executive Jamie L. Reynoso, CEO of Medicare Advantage, reported an open-market sale of 6,229 shares of Class A Common Stock at $5.26 per share. After this transaction, Reynoso directly holds 2,834,982 shares.
According to the disclosure, the shares were sold solely to cover tax withholding obligations tied to the vesting of 6.25% of restricted stock units that vested on July 3, 2026. The RSUs were originally granted on January 3, 2023 and vest in equal 6.25% quarterly installments through a final vesting date on January 1, 2027, subject to continued service. The company states these sales are mandated under its equity incentive plans as “sell to cover” transactions and are not discretionary trades by Reynoso.
Issuer submitted a Form 144 notice for proposed sales of Class A Common Stock. The filing lists multiple 10b5-1 sales attributed to Jamie Reynoso on 03/18/2026, 06/11/2026, 06/15/2026, and 06/17/2026, with respective share counts and dollar amounts shown. The filing also shows Restricted Stock Units dated 07/03/2026.
Clover Health Investments, Corp. Chief Executive Officer Andrew Toy reported an open-market sale of 313,476 shares of Class A common stock at $5.32 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations tied to the vesting of 6.25% of restricted stock units granted on January 1, 2023, under a mandatory “sell to cover” arrangement in the company’s equity incentive plans. Following the transaction, Toy directly owns 9,609,825 shares of Class A common stock. The remaining RSUs from this grant vest in equal 6.25% quarterly installments through January 1, 2027, contingent on continued service.
Clover Health Investments reported that the Centers for Medicare & Medicaid Services (CMS) has increased key quality ratings for its Medicare Advantage plans, which affect payments for 2027. CMS now shows the company’s PPO contract H5141 at 4.5 Stars for payment year 2027, up from 3.5 Stars in the 2026 Star Rating.
In addition, CMS’s updated guidance and system display that the 2026 Star Rating for Clover’s HMO contract H8010 has risen from 4.0 Stars to 4.5 Stars, also impacting payment year 2027 Quality Bonus Payments. These higher star ratings can support stronger revenue potential and competitiveness in the Medicare Advantage market.
Clover Health Investments executive Jamie L. Reynoso, CEO of Medicare Advantage, sold 2,360 shares of Class A common stock in an open-market transaction at a weighted average price of $4.78 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026.
After this sale, Reynoso directly holds 2,841,211 Clover Health shares, so the transaction represents a very small portion of her overall stake.